Abstract:Background: The identification of new serum biomarkers with high sensitivity and specificity is an important priority in pancreatic cancer research. Through an extensive proteomics analysis of pancreatic cancer cell lines and pancreatic juice, we previously generated a list of candidate pancreatic cancer biomarkers. The present study details further validation of four of our previously identified candidates: regenerating islet-derived 1 beta (REG1B), syncollin (SYCN), anterior gradient homolog 2 protein (AGR2), and lysyl oxidase-like 2 (LOXL2). Methods: The candidate biomarkers were validated using enzyme-linked immunosorbent assays in two sample sets of serum/plasma comprising a total of 432 samples (Sample Set A: pancreatic ductal adenocarcinoma (PDAC, n = 100), healthy (n = 92); Sample Set B: PDAC (n = 82), benign (n = 41), disease-free (n = 47), other cancers (n = 70)). Biomarker performance in distinguishing PDAC from each control group was assessed individually in the two sample sets. Subsequently, multiparametric modeling was applied to assess the ability of all possible two and three marker panels in distinguishing PDAC from disease-free controls. The models were generated using sample set B, and then validated in Sample Set A. Results: Individually, all markers were significantly elevated in PDAC compared to healthy controls in at least one sample set (p ≤ 0.01). SYCN, REG1B and AGR2 were also significantly elevated in PDAC compared to benign controls (p ≤ 0.01), and AGR2 was significantly elevated in PDAC compared to other cancers (p < 0.01). CA19.9 was also assessed. Individually, CA19.9 showed the greatest area under the curve (AUC) in receiver operating characteristic (ROC) analysis when compared to the tested candidates; however when analyzed in combination, three panels (CA19.9 + REG1B (AUC of 0.88), CA19.9 + SYCN + REG1B (AUC of 0.87) and CA19.9 + AGR2 + REG1B (AUC of 0.87)) showed an AUC that was significantly greater (p < 0.05) than that of CA19.9 alone (AUC of 0.82). In a comparison of early-stage (Stage I-II) PDAC to disease free controls, the combination of SYCN + REG1B + CA19.9 showed the greatest AUC in both sample sets, (AUC of 0.87 and 0.92 in Sets A and B, respectively). Conclusions: Additional serum biomarkers, particularly SYCN and REG1B, when combined with CA19.9, show promise as improved diagnostic indicators of pancreatic cancer, which therefore warrants further validation.

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays

Postoperative Serum CEA and CA125 Levels Are Supplementary to Perioperative CA19-9 Levels in Predicting Operative Outcomes of Pancreatic Ductal Adenocarcinoma.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9

A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity Over CA19-9 Alone

Identification of Serum Periostin as a Potential Diagnostic and Prognostic Marker for Colorectal Cancer.

Serum APN/CD13 As a Novel Diagnostic and Prognostic Biomarker of Pancreatic Cancer

The Systemic Assessment to the Clinical Value of Serum Tumor Markers for the Diagnosis of Pancreatic Cancer

Evaluation of Serum ATX and LPA As Potential Diagnostic Biomarkers in Patients with Pancreatic Cancer

CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

Serum Tumor Marker Carbohydrate Antigen 19-9 for the Diagnosis and Prognosis of Pancereatic Cancer

Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer

THE SIGNIFICANCE OF PRE- AND POSTOPERATIVE MEASUREMENT OF SERUM CA242 LEVELS IN PANCREATIC CANCER

Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

An Evaluation of the Diagnostic Value of CA19-9 and CEA Levels in Patients with Pancreatic Cancer

Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer

Serum Level of TSGF, CA242 and CA19-9 in Pancreatic Cancer.

Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples

Identification of COL12A1 as a novel diagnostic marker in pancreatic ductal adenocarcinoma by global proteome analysis

Validation of N -glycan markers that improve the performance of CA19-9 in pancreatic cancer